An MHRA Braille packaging defect notice shows why medicines wholesalers need strong product information, documentation and RP oversight.
Why Ongoing GDP Compliance Support Matters During Medicines Supply Pressure
UK medicines supply disruption and ongoing MHRA oversight highlight why businesses need continuous GDP compliance support and operational review.
Why Medicines Supply Pressure Makes Compliance Route Reviews More Important
Global medicines supply pressure is increasing regulatory and operational risk. Learn why compliance route reviews matter for GDP and WDA(H) operations.
WDA(H) Readiness in 2026: Why Compliance Matters Before and After Approval
UK medicines wholesale is growing, but compliance failures still trigger regulatory action. Learn why WDA(H) readiness and ongoing GDP compliance are critical.
Why Responsible Person Oversight Matters After UK Pharma Compliance Failures
Recent UK regulatory action highlights the risks of weak compliance oversight. Learn why Responsible Person and GDP quality support are critical.
Online Medicine Sales Show Why Route Control Matters
MHRA and eBay action against unauthorised medicine listings shows why supplier checks, customer qualification and route control matter.
Why Medicine Recall Readiness Matters for GDP Compliance
A recent MHRA medicine recall shows why wholesalers need strong GDP systems, traceability, Responsible Person oversight and recall readiness.
Why GDP Audit Readiness Matters as MHRA Inspections Continue in 2026
MHRA inspections remain risk-based across UK medicines wholesale. Learn why GDP audit and readiness support is critical for compliance and WDA(H) holders.
Why Supply Chain Pressure Makes Medicines Wholesale Planning More Important
UK healthcare supply pressures show why medicines wholesale businesses need clear GDP, supplier, customer and distribution planning before entering regulated activity.